Recommended Transfection Reagents in Different Cell Types. The reagents were tested in culture by using plasmid DNA (pDNA), short interfering RNA (siRNA), messenger RNA (mRNA), microRNA (miR), antisense oligonucleotide (ASO) or Cas9/sgRNA ribonucleoprotein (RNP) complex.
| Cell Type | All-Fect | Prime-Fect | Leu-Fect | Trans-Booster | mRNA-Fect | mRNA-Fect ULTRA | CRISP-Fect | |
|---|---|---|---|---|---|---|---|---|
| Primary Cells | Human umbilical cord blood derived mesenchymal stem cells (UCB-MSC) | pDNA* | pDNA* | pDNA mRNA |
||||
| Human bone marrow mesenchymal stem cells (BM-MSC) | pDNA [1] | pDNA | pDNA mRNA |
|||||
| Porcine vascular smooth muscle cells (VSMCs) | pDNA | pDNA mRNA |
||||||
| Human umbilical vein endothelial cells (HUVECs) | pDNA mRNA |
|||||||
| Bone marrow mononuclear cells from CML patients | siRNA | siRNA [2] | pDNA mRNA |
|||||
| Human foreskin fibroblast cells | pDNA* | |||||||
| Mouse osteoblasts | pDNA | |||||||
| Peripheral blood mononuclear cells (PBMCs) | pDNA | siRNA [3] | pDNA mRNA* |
mRNA | mRNA* | |||
| Human chondrocytes | siRNA* | |||||||
| Rat dorsal root ganglion (DRG) neurons | pDNA | mRNA | ||||||
| Cell Lines | Kidney fibroblast cells (293-T) | pDNA [4] saRNA* |
pDNA | pDNA mRNA |
||||
| Breast cancer cells (MDA-MB-231) | pDNA siRNA mRNA [5] |
siRNA | pDNA | pDNA mRNA |
mRNA | mRNA | RNP | |
| Kidney epithelial cells (MDCK) | siRNA | |||||||
| Breast cancer/melanoma cells (MDA-MB-436) | siRNA [7] | siRNA [7] pDNA, mRNA |
mRNA | mRNA | ||||
| Breast cancer cells (MDA-MB-468) | siRNA [6] | |||||||
| Breast cancer cells (Sum-149PT) | siRNA [6] | pDNA, mRNA siRNA [6] |
||||||
| Breast cancer cells (MCF-7) | pDNA [8] siRNA [8] |
pDNA siRNA [6] |
pDNA mRNA siRNA [6] |
mRNA | mRNA | |||
| Lymphoma cells (U-937) | pDNA | pDNA | ||||||
| Chronic myeloid leukemia cells (K562) | siRNA | pDNA mRNA* miR* |
mRNA | mRNA* | ||||
| Acute myeloid leukemia cells (KG1, KG1A, MV4-11, MOLM-13, THP-1) | siRNA | siRNA | siRNA [9] | mRNA* | mRNA* | |||
| Acute lymphocytic leukemia cells (RS4:11, SUP-B15) | siRNA [10] | siRNA [3] | siRNA [3] | mRNA | mRNA | |||
| Lung cancer cells (A549, Calu-3) | pDNA siRNA [11] |
siRNA [11] | mRNA* | mRNA* | ||||
| Colon cancer cells (HCT-116) | siRNA | siRNA | ||||||
| Myoblast cells (C2C12) | ||||||||
| T-cells (Jurkat) | pDNA* | mRNA* | mRNA* | RNP* | ||||
| Embryonic fibroblast cells (3T3) | mRNA [12] | mRNA [12] | ||||||
| Cervical carcinoma (HeLa) | mRNA [12] | mRNA [12] | ||||||
| Human hepatic cancer cell line (HepG2) | ||||||||
| Preclinical Models | Leukemia cells (RS4;11, MV4;11, K562, MOLM-13) | siRNA [9],[13] | siRNA [9] | |||||
| Lung cancer cells (A549, Calu-3) | mRNA* | mRNA* | ||||||
| Breast cancer cells (MDA-MB-436) | siRNA [7] | siRNA [7] | ||||||
| Biocompatibility | mRNA [12] | mRNA [12] siRNA [3],[14] |
mRNA* | |||||
| Mouse organ biodistribution (heart, bone marrow, spleen, liver, kidney) | mRNA [12] | siRNA [15] | mRNA [12] siRNA [14],[15] |
mRNA* |
pDNA: plasmid DNA | siRNA: short interfering RNA | mRNA: messenger RNA | saRNA: self-amplifying RNA | miR: microRNA | RNP: Cas9/sgRNA ribonucleoprotein | * Data on file
References
- Wang Y, et al. Modification of human BMSC with nanoparticles of polymeric biomaterials and plasmid DNA for BMP-2 secretion. J Surgical Research (2013) 183:8–17. doi: 10.1016/j.jss.2012.11.061
- Valencia-Serna J, et al. siRNA-mediated BCR-ABL silencing in primary chronic myeloid leukemia cells using lipopolymers. J Controlled Release (2019) 310:141–154. doi: 10.1016/j.jconrel.2019.08.018
- Nasrullah M, et al. Lipopolymer/siRNA Nanoparticles Targeting STAT5A Disrupts Proliferation of Acute Lymphoblastic Leukemia. ACS Pharmacol Transl Sci (2024). doi: 10.1021/ACSPTSCI.4C00336
- Neamnark A, et al. Aliphatic Lipid Substitution on 2 kDa Polyethylenimine Improves Plasmid Delivery and Transgene Expression. Mol Pharm (2009) 6:1798–1815. doi: 10.1021/MP900074D
- Thapa B, et al. TRAIL Therapy for Breast Cancer Treatment by Employing Lipopolymer mRNA Delivery. GEN Biotechnology (2022) 1:101–112. doi: 10.1089/GENBIO.2021.0007
- Parmar MB, et al. Additive Polyplexes to Undertake siRNA Therapy against CDC20 and Survivin in Breast Cancer Cells. Biomacromolecules (2018) 19:4193–4206. doi: 10.1021/ACS.BIOMAC.8B00918
- Santadkha T, et al. Improved delivery of Mcl-1 and survivin siRNA combination in breast cancer cells with additive siRNA complexes. Invest New Drugs (2022) 40:962–976. doi: 10.1007/S10637-022-01282-Y
- Thapa B, et al. Breathing New Life into TRAIL for Breast Cancer Therapy: Co-Delivery of pTRAIL and Complementary siRNAs Using Lipopolymers. Hum Gene Ther (2019) 30:1531–1546. doi: 10.1089/HUM.2019.096
- Ansari AS, et al. Lipopolymer mediated siRNA delivery targeting aberrant oncogenes for effective therapy of myeloid leukemia in preclinical animal models. J Controlled Release (2024) 367:821–836. doi: 10.1016/J.JCONREL.2024.02.018
- Mohseni M, et al. Therapeutic delivery of siRNA with polymeric carriers to down-regulate STAT5A expression in high-risk B-cell acute lymphoblastic leukemia. PLoS One (2021) 16. doi: 10.1371/JOURNAL.PONE.0251719
- KC R, et al. Cationic lipopolymer based siRNA delivery for experimental lung cancer treatment. Biomaterials Advances (2025) 177:214394. doi: 10.1016/j.bioadv.2025.214394
- Wang H, et al. Safe and Effective Delivery of mRNA Using Modified PEI-Based Lipopolymers. Pharmaceutics (2023) 15. doi: 10.3390/pharmaceutics15020410
- Yotsomnuk P, et al. Lipopolymers as the Basis of Non-Viral Delivery of Therapeutic siRNA Nanoparticles in a Leukemia (MOLM-13) Model. Biomolecules (2025) 15. doi: 10.3390/BIOM15010115
- Nasrullah M, et al. Suppressing t(4;11) Acute Leukemia by Lipopolymer Nanoparticle Delivery of siRNA Targeting KMT2A::AFF1. Adv Healthc Mater (2025). doi: 10.1002/ADHM.202502019
- Morales LC, et al. Biodistribution of Therapeutic Small Interfering RNAs Delivered with Lipid-Substituted Polyethylenimine-Based Delivery Systems. Mol Pharm (2023). doi: 10.1021/ACS.MOLPHARMACEUT.3C01077